Modified Cell Expansion and Uses Thereof

Abstract: the present disclosure relates to compositions and methods for enhancing t cell response and/or car cell expansion and/or maintenance in vivo and/or in vitro. for example, a method of enhancing t cell-based therapy comprises administering genetically modified t cells comprising a first chimeric antigen receptor (car) and a second car, wherein a binding domain of the first car binds a first antigen, and a binding domain of the second car binds a second antigen. the first antigen is different from the second antigen. in embodiments, the first car binds a surface molecule or antigen of a white blood cell.

Inventor(s): Lei Xiao, Zhiyuan Cao, Chengfei Pu, He Sun

CPC Classification: C07K14/7051 (PEPTIDES (peptides in foodstuffs ; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs ; preparations for medicinal purposes ; peptides containing beta-lactam rings ; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, ; ergot alkaloids of the cyclic peptide type ; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids ; macromolecular products derived from proteins ; preparation of glue or gelatine ; single cell proteins, enzymes ; genetic engineering processes for obtaining peptides ; compositions for measuring or testing processes involving enzymes ; investigation or analysis of biological material ))

Search for rejections for patent application number 20250188146